Literature DB >> 3111684

Separation and functional studies of the human lymphokine-activated killer cell.

K Roberts, M T Lotze, S A Rosenberg.   

Abstract

Cell separation studies were undertaken in an attempt to purify the lymphokine-activated killer (LAK) precursor cell. Null cells, prepared by the sequential depletion of monocytes, T- and B-lymphocytes from human peripheral blood mononuclear cells, were found to be potent mediators of LAK activity. Such preparations were Leu-11+ but Leu-4- and displayed high levels of natural killer activity. Incubation of these cells with recombinant interleukin 2 (IL-2) for periods in excess of 24 h induced LAK lysis of fresh tumor targets which were resistant to lysis by unstimulated null effectors. In contrast, lymphocytes which formed high affinity rosettes with sheep RBC (E+ lymphocytes) were poor mediators of both natural killer and LAK activity. Interleukin 2 stimulated null cells, retained a Leu-11+, Leu-4- phenotype, and expressed only low levels of receptors for IL-2 and transferrin. An increase in the number of binding sites, on null cells but not on T-cells, for Vicia villosa lectin with IL-2 stimulation was noted. Following IL-2 stimulation, null and T-cells were able to conjugate to K562 and fresh tumor but not to autologous lymphoblast targets.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3111684

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Heterogeneous lymphokine-activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires.

Authors:  B A Fox; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Heterogeneous binding and killing behaviour of human gamma/delta-TCR+ lymphokine-activated killer cells against K562 and Daudi cells.

Authors:  I Vollenweider; E Vrbka; W Fierz; P Groscurth
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

3.  Phenotypic and functional profile of peripheral blood mononuclear cells isolated from melanoma patients undergoing combined immunotherapy and chemotherapy.

Authors:  A Eisenthal; Y Skornick; I Ron; V Zakuth; S Chaitchik
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

4.  Evidence that interleukin-4 suppression of lymphokine-activated killer cell induction is mediated through monocytes.

Authors:  B Brooks; H Parry; J Lawry; R Rees
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

Review 5.  The development of new immunotherapies for the treatment of cancer using interleukin-2. A review.

Authors:  S A Rosenberg
Journal:  Ann Surg       Date:  1988-08       Impact factor: 12.969

6.  Phenotypic and functional analysis of lymphokine-activated killer (LAK) cell clones. Ability of CD3+, LAK cell clones to produce interferon-gamma and tumor necrosis factor upon stimulation with tumor targets.

Authors:  A S Chong; A Aleksijevic; P Scuderi; E M Hersh; W J Grimes
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  A protein fraction from aged garlic extract enhances cytotoxicity and proliferation of human lymphocytes mediated by interleukin-2 and concanavalin A.

Authors:  N Morioka; L L Sze; D L Morton; R F Irie
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

8.  Multiple leucocyte activation markers to detect neonatal infection.

Authors:  G Hodge; S Hodge; P Han; R Haslam
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

9.  Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer- and lymphokine-activated-killer-mediated cytotoxicity.

Authors:  P Correale; A Procopio; L Celio; M Caraglia; G Genua; V Coppola; S Pepe; N Normanno; I Vecchio; G Palmieri
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

10.  T-cell receptor beta gene rearrangements in clones derived from human CD4-8- cells expressing natural killer cell activity.

Authors:  S E Christmas; M Moore
Journal:  Immunology       Date:  1988-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.